Closing the Diagnostic Gap: Utilizing pTau217 for Scalable Alzheimer’s Disease Diagnosis

Sunday, July 12: 12:30-1:45 p.m.
Crowne Plaza Docklands (Docklands Suite)

This symposium explores the transformative role of pTau217 — a high-performance blood biomarker — in revolutionizing how we identify Alzheimer’s disease. As clinical practice shifts away from invasive spinal taps and costly PET scans, this session examines how scalable blood tests are bridging the "diagnostic gap," enabling earlier detection and expanding global access to disease modifying therapies.

The session will feature two speakers who will provide their expertise and insights on the clinical performance of pTau217 and its role in the clinical workflows.

Further refinement of the ATN framework may support drug development and facilitate patient care. This work explores integration of BBBMs with the ATN diagnostic framework, addressing their potential and limitations in capturing the multifaceted nature of AD.

Sponsored by: Roche

Improving Real World Representation in Alzheimer’s Disease Clinical Research and Treatment

Monday, July 13: 12:30-1:45 p.m.
Crowne Plaza Docklands (Docklands Suite)

This scientific symposium will review progress in plasma biomarkers as scalable diagnostic foundations, highlight persistent under-representation in patient demographics, and outline actionable steps to strengthen scientific understanding and promote widespread adoption.

Ensuring that emerging Alzheimer’s disease (AD) diagnostic strategies reflect real-world patient diversity is essential for accurate and equitable care. Today’s clinical research cohorts are largely composed of educated, health-aware individuals with limited demographic and pathological variability, constraining the generalizability of plasma-based tests. These gaps can lead to variable test performance across populations and care settings. Strengthening representation requires expanding awareness of blood‑based tools, improving clinician and community education, and generating real‑world evidence from heterogeneous groups.

Sponsored by: Danaher and Beckman Coulter Diagnostics

From Evidence to Life: A Clinical and Human Perspective in Early Alzheimer’s Disease

Monday, July 13: 6-7:30 p.m.
Crowne Plaza Docklands (Docklands Suite)

The approval of amyloid-targeted therapies (ATTs) marks a pivotal turning point in the treatment of early symptomatic Alzheimer's disease — the first therapies to demonstrate meaningful slowing of cognitive and functional decline by targeting the underlying biology of the disease. Yet approval is only the beginning. Translating robust clinical trial evidence into confident, safe, and effective real-world practice demands a different kind of conversation: one grounded not only in data, but in clinical experience, patient stories, and honest dialogue about what works, what challenges remain, and what it truly means for a patient to benefit.

This symposium brings together the world's leading experts in Alzheimer's disease — sharing their perspectives on critical questions that define the next chapter of integrating ATTs into clinical practice: Who is the right patient? How do we navigate safety in the real world? What does meaningful benefit look like — beyond the endpoint? And what does early identification and diagnosis mean to the patients and their care pathway?

Sponsored by: Eli Lilly and Company

Note: The content of this symposium may be promotional in nature and intended only for Healthcare Professionals.

Early Intervention in Alzheimer’s Disease: Building the Evidence From Pathology to Practice

Tuesday, July 14: 12:30-1:45 p.m.
Crowne Plaza Docklands (Docklands Suite)

This is an Eisai-organised and funded promotional symposium held during the Alzheimer's Association International Conference 2026 for healthcare professionals and will discuss Eisai medicines.

EMEA-LECA-26-00098 | Biogen-289573
Date of preparation: June 2026

Sponsored by: Eisai and Biogen

Note: The content of this symposium may be promotional in nature and intended only for Healthcare Professionals.

Emerging Data, Collective Impact: A Global Consortium Approach to Alzheimer’s Research

Wednesday, July 15: 12:30-1:45 p.m.
Crowne Plaza Docklands (Docklands Suite)

Global efforts in Alzheimer’s disease and related dementias are converging through collaborative consortia integrating diverse datasets, technologies, and expertise. Initiatives such as the Sex | Gender in Neurodegeneration Consortium (S|GN), Global Neurodegeneration Proteomics Consortium (GNPC), and NULISA NeuroData Commons are advancing “emerging data” resources: harmonized, cross-cohort datasets enabling deeper understanding of disease heterogeneity, biomarker discovery, and translational insights.

This symposium will showcase how consortium-driven infrastructure and partnerships accelerate early insights and expand access to high-value datasets: highlighting shared approaches, early scientific signals, and opportunities for broader participation to drive open, global discovery.

Sponsored by: Alzheimer's Disease Data Initiative